Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
TICOSPA: Efficacy of treat-to-target strategy suggested in axial spondyloarthritis
Key clinical point: A treat-to-target approach to axial spondyloarthritis that focused on reducing disease activity produced nominal improvement in a quality-of-life outcome.
Major finding: The ASAS Health Index improved by at least 30% in 47% of treat-to-target patients and 36% of usual-care patients.
Study details: TICOSPA, a multicenter, randomized study with 160 patients.
Disclosures: TICOSPA was sponsored by UCB. Dr. Moltó has been a consultant to and received research funding from AbbVie, Bristol-Myers Squibb, Merck, Pfizer, and UCB. Dr. Dougados has had financial relationships with AbbVie, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Merck, Pfizer, and UCB. Dr. van der Heijde has had financial relationships with more than 20 companies including UCB. Dr. Ramiro had been a consultant to or received research funding from AbbVie, Eli Lilly, MSD, Novartis and Sanofi.
Moltó A et al. Ann Rheum Dis. 2020 Jun;79[suppl 1]:413.